Highest-materiality recent filing
Sight Sciences Q1 revenue up 13% to $19.7M; raises FY 2026 guidance; Alcon damages $55.4M
Q1 revenue $19.7M (+13% YoY); net loss $13.0M ($0.24 loss per share) vs $14.2M loss in prior year.
Sight Sciences wins patent case vs Alcon; awarded $55.4M damages + ongoing royalty
Final judgment in Sight Sciences' patent infringement case against Alcon for Hydrus Microstent.
Order upholds jury finding that Alcon willfully infringed three Sight Sciences patents.
Sight Sciences Q4 revenue $20.4M (+7% YoY); guides 2026 revenue $82-88M
Q4 2025 revenue $20.4M (+7% YoY); Interventional Glaucoma $19.7M (+5% YoY); Dry Eye $0.7M vs $0.3M.
Sight Sciences reports Q4 2025 revenue up 7% YoY; FY 2025 revenue down 3% YoY
Q4 2025 total revenue $20.3M-$20.4M, +7% vs Q4 2024; Surgical Glaucoma +5%, Dry Eye +130%.
Sight Sciences Q3 revenue $19.9M, raises FY25 guidance; promotes COO and CFO
Surgical Glaucoma revenue $19.7M (+6% YoY); Dry Eye revenue $0.2M (-88%) as company focuses on reimbursed access.
Sight Sciences gets Medicare pricing for TearCare from Novitas and FCSO; $1,141.59 fee
Two MACs set jurisdiction-wide pricing for CPT 0563T (TearCare) at $1,141.59, effective Jan 1, 2025.
Sight Sciences extends interest-only period to Feb 2027, ups Tranche 3 to $25M
Interest-only period extended six months to February 1, 2027.
Sight Sciences cuts 20% workforce; CCO departs; reaffirms FY revenue guidance
Reduces headcount by 43 (~20% of global workforce); expects cash restructuring charge of $2.7M-$3.0M in Q3 2025.
Sight Sciences Q2 2025 revenue $19.6M (-8% YoY), raises FY25 revenue guidance to $72-76M
Net loss $11.9M ($0.23 loss per share) vs $12.3M loss in prior year.
Sight Sciences Q1 revenue $17.5M (-9% YoY); reaffirms FY25 guidance $70-75M; lowers expense guide
Total revenue $17.5M, down 9% YoY; Surgical Glaucoma $17.1M (-6% YoY); Dry Eye $0.4M (-60% YoY).
Sight Sciences reports Q4 revenue $19.1M (+2% YoY); guides FY2025 revenue down 6%-12%
Q4 total revenue $19.1M (+2% YoY); Surgical Glaucoma $18.8M (+9%), Dry Eye $0.3M (down from $1.6M).
Sight Sciences prelim Q4 2024 rev $18.9-19.1M (+1% YoY); Surgical Glaucoma +9%
Surgical Glaucoma revenue $18.7-18.8M (+9% YoY at midpoint); Dry Eye rev $0.2-0.3M vs $1.6M prior year.
Sight Sciences reports Q3 2024 results, COO retirement, and new leadership appointments
Q3 2024 revenue was $20.2M, up 1% YoY; net loss narrowed to $11.1M ($0.22 per share) from $13.0M.
Four MACs (Palmetto GBA, CGS, NGS, WPS) published final LCDs effective Nov 17, 2024, confirming coverage for single MIGS with phaco.
Sight Sciences Q2 revenue $21.4M (-9% YoY); net loss $0.25/sh; FY guidance cut to $81M-$83M
Total revenue $21.4M (-9% YoY); net loss $12.3M ($0.25/sh) vs $14.8M loss in Q2 2023.
Sight Sciences: Draft Medicare LCDs propose no coverage restrictions for OMNI and SION
Five MACs published draft LCDs on MIGS not proposing specific coverage criteria for OMNI (canaloplasty+trabeculotomy) or SION (goniotomy).
Sight Sciences Q1 revenue $19.3M (+2% YoY); wins $34M jury verdict against Alcon
Q1 2024 revenue $19.3M (+2% YoY); Surgical Glaucoma $18.3M (+5%), Dry Eye $1.0M (-32%).
Sight Sciences wins $34M patent verdict against Alcon over Hydrus Microstent
Jury found Alcon willfully infringed three Sight Sciences patents (U.S. 8,287,482, 9,370,443, 11,389,328) related to Hydrus Microstent.
Sight Sciences FY2023 revenue $81.1M (+14%); guides FY2024 $81-85M (0-5% growth)
Q4 2023 revenue $18.8M (-9% YoY); net loss $10.7M ($0.22/sh) vs $16.9M loss ($0.35/sh) prior year.
Sight Sciences closes $65M credit facility with Hercules Capital, draws $35M to refinance prior debt
$35M funded at closing from $65M total facility; used to repay $37.7M MidCap term loan.
Sight Sciences reports MACs delay effective date of LCDs impacting OMNI and SION to January 29, 2024
Five MACs delayed effective date of local coverage determinations on Micro-Invasive Glaucoma Surgery from Dec 24, 2023 to Jan 29, 2024.
Five MACs classify Sight Sciences' OMNI procedures as investigational; 63% of revenue at risk
Four new MACs (Palmetto, Celerian, NGS, Noridian) plus prior WPS LCD classify OMNI canaloplasty/trabeculotomy as investigational, effective Dec 24, 2023.
Sight Sciences Q3 revenue up 7% to $20.0M, withdraws FY 2023 guidance on LCD uncertainty
Q3 revenue $20.0M (+7% YoY); Surgical Glaucoma $18.4M (+8% YoY); Dry Eye $1.6M (-1% YoY).
WPS LCD classifies OMNI procedure as investigational, effective Dec 24, 2023; WPS states ~8% of 2022 Surgical Glaucoma revenue.
Sight Sciences cuts 10% of workforce, expects $1.3M charge, reaffirms FY2023 guidance
Reduces headcount by 25 employees (~10% of global workforce) under restructuring plan.
Sight Sciences cuts FY2023 guidance to $80-82M, cites LCD uncertainty; appoints Matt Link CCO
Q3 guidance $19-20M; FY guidance cut to $80-82M from $89-94M (12-15% YoY growth).
Sight Sciences Q2 revenue $23.5M (+36% YoY); net loss narrows to $14.8M; reaffirms FY guidance
Revenue $23.5M, +36% YoY; Surgical Glaucoma $21.4M (+35%), Dry Eye $2.1M (+56%).
Reaffirmed FY 2023 revenue guidance of $89-94M (25-32% YoY growth) and average quarterly adjusted opex of ~$30.5M.
Sight Sciences reaffirms FY23 revenue guidance; WPS proposes limiting MIGS coverage for OMNI
Reaffirmed FY2023 revenue guidance of $89M-$94M (25%-32% growth YoY); quarterly adjusted opex ~$30.5M.
Sight Sciences Q1 revenue up 26% to $18.8M, net loss $17.1M; reaffirms FY2023 guidance
Revenue $18.8M (+26% YoY); Surgical Glaucoma $17.3M (+25%), Dry Eye $1.5M (+47%).
Sight Sciences appoints Alison Bauerlein as CFO; interim CFO Rodberg steps down
Alison Bauerlein named CFO & Treasurer effective April 3, 2023, succeeding interim CFO Jim Rodberg.
Sight Sciences Q4 2022 revenue up 40% YoY to $20.5M; guides 2023 revenue $89-94M
Full-year 2022 revenue $71.3M (+46% YoY); Surgical Glaucoma $65.6M (+41%), Dry Eye $5.7M (+133%).
Preliminary Q4 2022 total revenue $20.4M-$20.6M (+40% YoY); full-year revenue $71.2M-$71.4M (+46% YoY).
Sight Sciences Q3 revenue $18.7M (+43% YoY); narrows FY22 guidance to $70-72M
Surgical Glaucoma revenue $17.1M (+37% YoY); Dry Eye revenue $1.6M (+145% YoY).
Sight Sciences Q2 revenue $17.2M (+37% YoY); net loss $23.8M; FY22 guidance $68-72M
Surgical Glaucoma revenue $15.9M (+33% YoY); Dry Eye revenue $1.3M (+143% YoY).
As previously disclosed, on April 21, 2025, the Board of Directors (the “Board”) of Sight Sciences, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Gerhard F. Burbach to the Board.
On April 21, 2025, the Board of Directors (the “Board”) of Sight Sciences, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Gerhard F. Burbach to the Board.
On November 1, 2024, Sam Park, Chief Operating Officer of the Company, informed the Board of Directors of the Company (the "Board") of his decision to retire effective as of November 15, 2024.
Effective as of November 4, 2024, the Board appointed Brenton Taylor as the Company’s Executive Vice President of Operations and designated him to succeed Mr. Park as the Company’s principal operating officer.
Effective September 11, 2023, Matthew Link was appointed by the board of directors (the “Board”) of Sight Sciences, Inc. (the “Company”) to serve as the Company’s Chief Commercial Officer.
Effective April 3, 2023, Alison Bauerlein was appointed by the Board of Directors (the “Board”) of Sight Sciences, Inc. (the “Company”) to serve as the Company’s Chief Financial Officer and Treasurer.
Effective January 5, 2023, Mack Hicks stepped down as a Class II director and as a member of the Audit Committee of the Board
Effective January 9, 2023, Jesse Selnick, the Company’s Chief Financial Officer and Treasurer, stepped down from his positions with the Company effective immediately.
Effective January 9, 2023, Jim Rodberg, the Company’s Vice President of Finance and Corporate Controller, was appointed by the Board of Directors of the Company (the “Board”) to serve as interim Chief Financial Officer and Treasurer until the appointment of Mr. Selnick’s successor.
On July 15, 2022, the Board of Directors (the “Board”) of Sight Sciences, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee (the “Nominating Committee”), appointed Tamara Fountain, M.D. to the Board.
On March 15, 2022, the Board of Directors (the “Board”) of Sight Sciences, Inc. (the “Company”) appointed Brenda Becker to the Board.
On February 28, 2022, Andrew Offer tendered his resignation as a Class I director of the Board of Directors (the “Board”) of Sight Sciences, Inc. (the “Company”), and stepped down from the Board and its Audit Committee, effective on March 4, 2022 (the “Effective Date”).
Max materiality 0.90 · Median 0.70 · Most common event earnings